<DOC>
	<DOCNO>NCT01508364</DOCNO>
	<brief_summary>This observational study investigate use Nexavar first target therapy patient advance renal cell carcinoma .</brief_summary>
	<brief_title>Nexavar First Targeted Therapy Patients With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Patients diagnosis advance Renal cell carcinoma ( RCC ) decision take investigator prescribe Nexavar . Patients fail cytokine therapy suitable cytokine Nexavar first target drug treatment . Prior target therapy RCC Contraindications Nexavar describe Summary Product Characteristics ( SPC ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>renal cell carcinoma , first target therapy , observational study</keyword>
</DOC>